Altimmune, Inc. filings document a late clinical-stage biopharmaceutical issuer focused on pemvidutide for serious liver diseases, along with the capital structure used to support that development. Its Form 8-K reports cover operating-result announcements, underwriting agreements, registered direct and at-the-market equity programs, pre-funded warrants, common stock warrants and loan agreement amendments.
Altimmune’s proxy and annual meeting materials disclose shareholder voting matters, governance procedures, executive compensation information and amendments to its certificate of incorporation, including authorized-share matters. The filings also identify its common stock as listed on The Nasdaq Global Market under the symbol ALT.
Altimmune, Inc. Schedule 13G/A reports that Tang Capital Management, LLC and related entities and persons beneficially own 666,022 shares of common stock, representing 0.3% of the class. The filing states the percent is calculated from 194,199,358 shares outstanding as of April 24, 2026 as shown in a prospectus filed on April 24, 2026. The filing lists shared voting and dispositive power among Tang Capital Management, LLC, Tang Capital Partners International, LP, and Kevin Tang, and affirms the position falls within the "Ownership of 5 Percent or Less of a Class" category.
Altimmune, Inc. reported another quarter of operating losses as it continues to advance its liver disease pipeline. For the three months ended March 31, 2026, the company generated no product revenue and recorded a net loss of $22.6 million, compared with $19.6 million a year earlier, driven by research and development spending of $16.2 million and general and administrative expenses of $8.1 million.
Altimmune’s balance sheet strengthened meaningfully, with cash, cash equivalents, restricted cash and short‑term investments totaling $331.6 million and total liabilities of $51.6 million at quarter end, supported by recent equity raises including a January 2026 registered direct offering and an April 2026 underwritten offering that brought in net proceeds of about $211.2 million and added common stock warrants with potential additional gross proceeds of $225 million if fully exercised.
The company is preparing its global PERFORMA Phase 3 trial of lead candidate pemvidutide in MASH, while running Phase 2 studies in alcohol use disorder and alcohol‑associated liver disease. With accumulated deficit of $672.0 million and ongoing negative operating cash flow, Altimmune remains dependent on its substantial cash reserves and capital markets access to fund these long, expensive clinical programs.
Altimmune, Inc. reported another quarter of operating losses as it continues to advance its liver disease pipeline. For the three months ended March 31, 2026, the company generated no product revenue and recorded a net loss of $22.6 million, compared with $19.6 million a year earlier, driven by research and development spending of $16.2 million and general and administrative expenses of $8.1 million.
Altimmune’s balance sheet strengthened meaningfully, with cash, cash equivalents, restricted cash and short‑term investments totaling $331.6 million and total liabilities of $51.6 million at quarter end, supported by recent equity raises including a January 2026 registered direct offering and an April 2026 underwritten offering that brought in net proceeds of about $211.2 million and added common stock warrants with potential additional gross proceeds of $225 million if fully exercised.
The company is preparing its global PERFORMA Phase 3 trial of lead candidate pemvidutide in MASH, while running Phase 2 studies in alcohol use disorder and alcohol‑associated liver disease. With accumulated deficit of $672.0 million and ongoing negative operating cash flow, Altimmune remains dependent on its substantial cash reserves and capital markets access to fund these long, expensive clinical programs.
Altimmune, Inc. reported first quarter 2026 results and a business update focused on its lead drug pemvidutide for serious liver diseases. For the three months ended March 31, 2026, the company generated no revenue, recorded operating expenses of $24.2 million, and reported a net loss of $22.6 million (basic and diluted net loss per share of $0.18), compared with a net loss of $19.6 million a year earlier.
Cash, cash equivalents and restricted cash were $97.6 million and short-term investments were $233.9 million as of March 31, 2026, and the company highlighted total cash, cash equivalents and short-term investments of $535 million as of April 30, 2026 following a recent financing. Total assets were $335.6 million and stockholders’ equity was $284.0 million as of March 31, 2026, with 130,221,154 common shares issued and outstanding.
Altimmune plans to initiate the PERFORMA Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2026, and expects topline Phase 2 data in alcohol use disorder (AUD) and enrollment completion in the RESTORE Phase 2 alcohol-associated liver disease (ALD) trial this year. Pemvidutide holds FDA Fast Track designations for MASH and AUD, and Breakthrough Therapy Designation for MASH.
Altimmune, Inc. reported first quarter 2026 results and a business update focused on its lead drug pemvidutide for serious liver diseases. For the three months ended March 31, 2026, the company generated no revenue, recorded operating expenses of $24.2 million, and reported a net loss of $22.6 million (basic and diluted net loss per share of $0.18), compared with a net loss of $19.6 million a year earlier.
Cash, cash equivalents and restricted cash were $97.6 million and short-term investments were $233.9 million as of March 31, 2026, and the company highlighted total cash, cash equivalents and short-term investments of $535 million as of April 30, 2026 following a recent financing. Total assets were $335.6 million and stockholders’ equity was $284.0 million as of March 31, 2026, with 130,221,154 common shares issued and outstanding.
Altimmune plans to initiate the PERFORMA Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2026, and expects topline Phase 2 data in alcohol use disorder (AUD) and enrollment completion in the RESTORE Phase 2 alcohol-associated liver disease (ALD) trial this year. Pemvidutide holds FDA Fast Track designations for MASH and AUD, and Breakthrough Therapy Designation for MASH.
State Street Corporation reports shared beneficial ownership of 5.5% of Altimmune Inc. common stock. The filing states 7,145,550 shares as the number of shares for which State Street has shared dispositive power, with 7,012,433 shares of shared voting power, as of 03/31/2026. The schedule identifies affiliated investment-advisory subsidiaries and is signed by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer, on 05/12/2026.
Altimmune, Inc. ownership filing: an investment group led by Viking Global reports beneficial ownership of 13,400,000 shares of Altimmune common stock, representing 6.7% of the class based on 194,199,358 shares outstanding as of April 24, 2026. The holdings reflect 4,690,000 shares owned by Viking Global Opportunities (VGOP) and 2,010,000 shares owned by Viking Global Opportunities Vintage IV (VGOVIV), plus corresponding 6,700,000 warrants exercisable at $3.00 per share that give the reporting group the right to purchase additional shares. Ownership is reported across multiple related entities and two named individuals as shared voting and dispositive power.
Altimmune reports Schedule 13G ownership by TCG Crossover funds and Chen Yu. The filing lists aggregate shared voting and dispositive power of 10,000,000 shares for each TCG Crossover fund entity (reported as 5.0% of the class) and reports 20,000,000 shares attributable to Chen Yu (reported as 9.8% of the class). The filing states 194,199,358 shares outstanding as of April 24, 2026 following an underwritten offering and references an additional 10,000,000 shares issuable upon exercise of Common Warrants held by the TCG Crossover entities.
Altimmune, Inc. director Teri L. Lawver received a grant of stock options as part of non-employee director compensation. The award covers 48,800 stock options with an exercise price of $2.82 per share and expires on May 1, 2036.
The options relate to 48,800 shares of common stock and were granted at no cost. They vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on continued board service. After this grant, the filing shows 48,800 derivative securities held.
Altimmune, Inc. director Catherine A. Sohn received a grant of stock options as part of her non-employee director compensation. She was awarded 48,800 stock options to buy common stock at an exercise price of $2.82 per share, with no cash paid at grant.
The options become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to her continued service. Any unexercised options expire on May 1, 2036, and her reported post-transaction holdings in this option grant are 48,800 options.
Altimmune, Inc. director Diane Jorkasky received a grant of stock options covering 48,800 shares of common stock as board compensation. The options carry an exercise price of $2.82 per share and expire on May 1, 2036. The shares underlying the option vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, conditioned on her continued service as a non-employee director.
Altimmune, Inc. director Klaus Schafer received a grant of stock options as part of non-employee director compensation. The award covers 48,800 options to buy common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.
The options relate to 48,800 shares of common stock and were granted at no cost. They vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on his continued board service. After this grant, he holds 48,800 options directly.